Clinical Trial Update: Haploidentical NK Cell Infusion in Malignant Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating haploidentical natural killer (NK) cell infusion for malignant melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Haploidentical NK cell infusion

Snippet

Sponsor: Seoul National University Hospital | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED